Ro Pharmacy

Emerging

NY digital health platform with owned pharmacy at $350M revenue in men's health, women's health, and GLP-1 weight management; $876M raised competing with Hims & Hers for DTC telehealth prescription delivery.

Company Overview

About Ro Pharmacy

Ro is a New York-based digital health platform — backed with $876 million raised from General Catalyst, SignalFire, L Catterton, and others at a peak $7 billion valuation — providing telemedicine consultations, prescription management, and pharmacy-grade medication delivery for men's health (erectile dysfunction, hair loss under the Roman brand), women's health (fertility, menopause under the Rory brand), primary care (Ro Primary Care), and weight management (body program with GLP-1 medications). Founded in 2017 by Zachariah Reitano, Rob Schutz, and Saman Rahmanian, Ro generated approximately $350 million in revenue in 2024, serving over 2 million patients who have completed consultations through its platforms.

Business Model & Competitive Advantage

Ro's vertically integrated model is the operational differentiator: rather than contracting with third-party pharmacies (as most telehealth platforms do), Ro owns and operates its own pharmacy infrastructure (Ro Pharmacy, a licensed dispensary in multiple states). This vertical integration enables the $99/month ED medication subscription, the same-day compounded semaglutide dispensing for weight management, and the generic medication pricing that drives patient economics for chronic condition management. The asynchronous consultation model (patients complete a health questionnaire, a licensed physician reviews it and issues a prescription) enables 24/7 prescription access without appointment scheduling.

Competitive Landscape 2025–2026

In 2025, Ro competes in the direct-to-consumer telehealth and prescription delivery market with Hims & Hers (NYSE: HIMS, the primary direct competitor for men's and women's health), Noom (weight management), and Amazon Clinic (AMZN, telehealth expansion) for digital health patient acquisition. Hims & Hers has grown aggressively in GLP-1 compounded semaglutide (weight management) and gained significant scale, while Ro's Roman and Rory brands retain strong brand equity in their core men's and women's health audiences. The compounded GLP-1 market is in regulatory flux — FDA policies on compounding pharmacies and Novo Nordisk's Ozempic drug shortage status affect both Ro's and Hims's GLP-1 businesses. The 2025 strategy focuses on primary care membership growth, GLP-1 program expansion, and building the chronic condition management platform (diabetes, hypertension) beyond the branded health conditions.

Revenue
$350M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

Ro Pharmacy is an emerging player bringing innovative solutions to the Healthcare market.

Growth Stage

Ro Pharmacy has achieved $350M in revenue, demonstrating strong product-market fit.

Frequently Asked Questions

Not So Random Others

Brisk

Consumer Food & Beverage
B2cManufacturingNorth AmericaFortune500

Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione

Altria

Consumer Goods
B2cManufacturingNorth AmericaPublicFortune500

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s

Hermes Robotics

Manufacturing
B2bHardwareManufacturingAi PoweredAutomationStartup

Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma

Duckie

Infrastructure
B2bPlatformAi PoweredAutomation

Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit

Zeffy

Nonprofit Tech
B2bSaas

Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs

Oda Studio

Real Estate & Property Tech
B2bProptechAi PoweredSaas

Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal

Compare Ro Pharmacy with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Ro Pharmacy

Claim This Profile

Are you from Ro Pharmacy? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Ro Pharmacy Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Ro Pharmacy vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →